Press Release

Daewoong Pharmaceutical’s press release

NEW 1 Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics: 2025-0611

NEW 2 Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on ‘Bersiporocin’ at ATS 2025, Highlights Global Patient Demographics: 2025-0604

NEW 3 Daewoong Pharmaceutical Announces Financial Results for 2024: 2025-0210

Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics 2025-06-11
Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on ‘Bersiporocin’ at ATS 2025, Highlights Global Patient Demographics 2025-06-04
Daewoong Pharmaceutical Announces Financial Results for 2024 2025-02-10
Daewoong Pharmaceutical Announces Third Quarter 2024 Financial Results 2024-11-01
Daewoong Pharmaceutical Unveils ‘Innovative Drug Delivery Technologies’ in Milan—From World’s First Microneedle Therapy to Once-a-Month Obesity Treatment 2024-10-14
Daewoong Pharmaceutical Announces Second Quarter 2024 Financial Results 2024-08-09
Daewoong Pharmaceutical's 'Fexuprazan' Expands into Latin America: Enters $300 Million Market in Mexico, Chile, and Ecuador 2024-08-08
Daewoong Pharmaceutical Receives Positive Recommendation from IDMC to Continue Developing its First-in-Class PRS Inhibitor, Bersiporocin 2024-07-29
Daewoong Pharmaceutical Presented Superiority of Enavogliflozin at 84th ADA Scientific Sessions 2024-07-12

1 2 3 4 5 6 7 8 9 10 다음 페이지

Search